This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Geneva Pharmaceuticals Technology Corporation
Geneva Pharmaceuticals Technology Corporation, commonly referred to as Geneva Pharmaceuticals, is a leading player in the pharmaceutical industry, headquartered in the United States. Founded in the early 2000s, the company has established a strong presence in key operational regions, focusing on the development and manufacturing of high-quality generic and specialty pharmaceuticals. With a commitment to innovation, Geneva Pharmaceuticals offers a diverse portfolio of products, including advanced formulations and delivery systems that set them apart in the market. Their dedication to quality and compliance has earned them a reputable position within the industry, marked by significant milestones in regulatory approvals and product launches. As a trusted partner in healthcare, Geneva Pharmaceuticals continues to contribute to improved patient outcomes through accessible and effective medication solutions.
DitchCarbon Score
How does Geneva Pharmaceuticals Technology Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Geneva Pharmaceuticals Technology Corporation's score of 45 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Geneva Pharmaceuticals Technology Corporation, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Sandoz Group AG, and any emissions data or climate commitments would be inherited from this parent organisation. As of now, Geneva Pharmaceuticals has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The absence of documented reduction targets suggests that the company may still be in the early stages of formalising its climate commitments. Given its affiliation with Sandoz Group AG, any relevant emissions data or climate strategies would be derived from the parent company's initiatives. However, without specific figures or commitments from Sandoz, it is challenging to provide a detailed overview of Geneva Pharmaceuticals' carbon footprint or climate action plans. In summary, while Geneva Pharmaceuticals Technology Corporation is part of a larger corporate family with potential climate initiatives, it currently lacks specific emissions data and reduction commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 75,620,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 158,430,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Geneva Pharmaceuticals Technology Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
